CRISPR Therapeutics AG
CRSP
$43.34
-$2.19-4.81%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 37.31M | 202.83M | 202.23M | 271.71M | 371.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.31M | 202.83M | 202.23M | 271.71M | 371.21M |
| Cost of Revenue | 430.90M | 463.89M | 484.70M | 498.59M | 517.58M |
| Gross Profit | -393.59M | -261.06M | -282.47M | -226.88M | -146.38M |
| SG&A Expenses | 72.98M | 71.33M | 72.20M | 71.76M | 76.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 503.88M | 535.22M | 556.90M | 570.35M | 593.74M |
| Operating Income | -466.57M | -332.39M | -354.68M | -298.64M | -222.54M |
| Income Before Tax | -362.67M | -236.47M | -263.15M | -214.84M | -150.72M |
| Income Tax Expenses | 3.59M | 3.12M | 2.66M | 2.29M | 2.89M |
| Earnings from Continuing Operations | -366.25 | -239.59 | -265.80 | -217.14 | -153.61 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -366.25M | -239.59M | -265.80M | -217.14M | -153.61M |
| EBIT | -466.57M | -332.39M | -354.68M | -298.64M | -222.54M |
| EBITDA | -447.31M | -313.08M | -335.17M | -279.02M | -202.70M |
| EPS Basic | -4.36 | -2.80 | -3.20 | -2.70 | -1.95 |
| Normalized Basic EPS | -2.70 | -1.73 | -1.98 | -1.67 | -1.19 |
| EPS Diluted | -4.37 | -2.84 | -3.24 | -2.73 | -1.97 |
| Normalized Diluted EPS | -2.70 | -1.74 | -2.00 | -1.68 | -1.21 |
| Average Basic Shares Outstanding | 337.41M | 331.64M | 325.82M | 319.99M | 316.87M |
| Average Diluted Shares Outstanding | 337.41M | 333.28M | 327.45M | 321.62M | 318.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
